Evotec SEEVO +1.11%64 OCF Margin % is -2.50% as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Evotec SE ranks worse than 67.36% on this metric.
The historical rank and industry rank for Evotec SE's OCF Margin % or its related term are showing as below:
EVO'
s OCF Margin % Range Over the Past 10 Years
Min: -1.16 Med: 9.2 Max: 41.62
Current: 2.46
During the past 13 years, the highest OCF Margin % of Evotec SE was 41.62%. The lowest was -1.16%. And the median was 9.20%.
EVO's OCF Margin % is ranked worse than 67.36% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs EVO: 2.46
Evotec SE OCF Margin % Related Terms
Evotec SE OCF Margin % Historical Data
* Premium members only.
The historical data trend for Evotec SE's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Evotec SE's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a OCF Margin % of -2.50% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #646 out of 959 companies in the Drug Manufacturers industry, placing it in the top 67.4%.
Is Evotec SE's OCF Margin % too high?
Evotec SE's current OCF Margin % is -2.50%. Based on the distribution chart, Evotec SE ranks #646 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #646 out of 959 companies for OCF Margin %. This places Evotec SE in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current OCF Margin % is -2.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current OCF Margin % is -2.50%. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Evotec SE (EVO), the current OCF Margin % is -2.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
OCF Margin %: -2.50%
GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
